CIBC Bancorp USA’s Aldeyra Therapeutics ALDX Stock Holding History

CIBC Bancorp USA’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,237	Closed	-$22.4K	–	1936
2026 Q1	$22.4K	Buy	+13,237	New	+$58K	﹤0.01%	1737

Other funds holding ALDX

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CIBC Bancorp USA's ALDX Position: Q2 2026 in Review

CIBC Bancorp USA sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 13,237 shares — an estimated $22.4K sold.

CIBC Bancorp USA first reported a position in ALDX in Q1 2026 and held it in 1 quarter. The position peaked at $22.4K in Q1 2026. 98 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

CIBC Bancorp USA reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
CIBC Bancorp USA sold 13,237 Aldeyra Therapeutics shares in Q2 2026, an estimated $22.4K.
CIBC Bancorp USA first reported a position in Aldeyra Therapeutics in Q1 2026 and held it in 1 quarter.
CIBC Bancorp USA's Aldeyra Therapeutics position peaked at $22.4K in Q1 2026.
98 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.